No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Medicamen Biotech Ltd. is an Indian pharmaceutical company primarily engaged in the research, development, manufacturing, marketing, and distribution of finished drug formulations and Active Pharmaceutical Ingredients (APIs) across India. The firm's extensive product line includes various dosage forms such as non-beta lactam tablets, beta and non-beta lactam capsules, liquid and dry syrups, as well as topical ointments and creams. These offerings cater to a broad spectrum of therapeutic categories, including gastrointestinal disorders, pain management, anti-infectives, pediatric care, dermatology, women's health and musculoskeletal conditions (gynecology and rheumatology), diabetes, cardiovascular health, oncology, and central nervous system ailments. Founded in 1993, Medicamen Biotech Limited is headquartered in New Delhi, India.
www.medicamen.comNo one on the platform currently holds MEDICAMEQ.BO.
No tracked institution reports a position in MEDICAMEQ.BO as of their last filing.
No one on the platform has traded MEDICAMEQ.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.5% | 8.0% | 9.7% | — | — | — |
| Rev. Growth % | 21.7% | 11.9% | ||||
| Profit Margin % | 4.9% | 7.8% | 8.5% | |||
| Free Cash Flow Margin % | -20.1% | -9.5% | -9.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.3B | +16.4% | $11.64 | $11.64–$11.64 | — | 1 |
| 2028 | $1.4B | +10.1% | $12.34 | $12.34–$12.34 | — | 1 |
| 2029 | $1.7B | +15.0% | $14.71 | $14.71–$14.71 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-09 | $3.50 | $1.61 | -54.0% |
| 2025-11-12 | $3.50 | $1.56 | -55.4% |
| 2025-08-12 | $3.50 | $1.18 | -66.3% |
| 2025-05-30 | $3.50 | $1.90 | -45.7% |
| 2025-02-11 | $3.50 | $2.30 | -34.3% |
| 2024-11-14 | $3.50 | $1.15 | -67.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MEDICAMEQ.BOMedicamen Biotech Limited | $343.50 | +7.95% | $4.7B | — |
| ALBERTDAVD.NSAlbert David Limited | $860.45 | +1.00% | $4.9B | — |
| BAFNAPH.NSBafna Pharmaceuticals Limited | $309.00 | +0.55% | $7.3B | — |
| KILITCH.BOKilitch Drugs (India) Limited | $186.30 | -0.11% | $6.6B | — |
| KILITCH.NSKilitch Drugs (India) Limited |
| $188.82 |
| -0.73% |
| $6.6B |
| — |
| MEDICO.BOMedico Remedies Limited | $35.48 | -1.09% | $3.0B | — |
| MEDICO.NSMedico Remedies Limited | $35.33 | -0.98% | $2.9B | — |
Source: Financial Modeling Prep · peers by sector/industry